JAN 20, 2016 12:47 PM PST

Path of Chemo Drugs Now Lit by New Peptide Tags

WRITTEN BY: Xuan Pham
Fluorescent peptide tags light the path of chemo drugs

When x-ray radiation fails or when complete surgical removal is not possible, chemotherapy is the next best available option to treat cancer cells. Although the treatment can be highly potent, doctors have limited knowledge of where the drug ends up once it is administered to the patient. To solve this problem, researchers from Ohio State University (OSU) have devised a way to tag anti-cancer drugs and follow its path in real time.
 
Tracking anti-cancer drugs in the patients has been attempted before. However, these attempts have been thwarted because organic tracker dyes dissolved too quickly before reaching the targets. Conversely, other longer-lasting tracker molecules were too toxic for the body to be of clinical use.
 
Led by Dr. Mingjun Zhang, biomedical engineering professor at OSU, the research team created a new nanoparticle tracking technology that is based on naturally occurring small peptide molecules. To the nanoparticle, the team attached a fluorescent tag that can be optically detected only once the drug is active in the body.
 
The real innovation in this new design lays in the “inherent biocompatibility” of the florescent nanoparticle. Because it is made from amino acids, the peptide causes little to no harm to the body’s cells. Furthermore, once the peptides have served its tracking purpose, the body is able to process it easily.
 
Testing the technique on doxorubicin, a commonly prescribed chemotherapy drug, the researchers noted that the fluorescence signal could be detected over long periods. Tracking this and other chemotherapy drugs could allow doctors to measure the speed and efficacy of a drug inside a patient. And because the fluorescence signal is only detectable once the drug is active, doctors can clearly trail the drug’s path and time its release.
 
As with any drug compounds, chemotherapy drugs can have different behavioral profiles in different patients. “In some people, chemotherapy can take effect in a few minutes, in others it can take hours, and there are also cases where it never takes effect,” says Prof. Zhang.
 
In the case of cancer, knowing when and where the drug acts is especially crucial, considering the fact that chemotherapy drugs are actually highly poisons to the body’s cells. Chemotherapy drugs target rapidly dividing cells and kills most cancerous cells. Unfortunately, most drugs can’t yet discriminate between cancer cells and healthy cells, so patients often experience “collateral damages” – negative side-effects from the therapy.
 
The ability to track the chemo drug in real time could greatly expand our understanding of where the drugs land and how they affect the patient, positively and negatively. The tracking technology could also be combined with targeted chemotherapies currently being developed, allowing researchers to truly minimize the collateral damages inflicted on cancer patients.
 

 
Additional source: MNT
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 25, 2018
Clinical & Molecular DX
APR 25, 2018
Why is dementia going unnoticed in hospitals?
A study in the UK showed that while the rate of diagnosis for dementia is improving, more than a third of all dementia patients still go undiagnosed. The n...
MAY 28, 2018
Clinical & Molecular DX
MAY 28, 2018
Bacterial Toxin Linked to Inflammatory Bowel Disease
Scientists have found evidence that it's not a bacterium, but one of its toxins, that is connected to, and possibly causing intestinal dysfunction....
JUN 20, 2018
Genetics & Genomics
JUN 20, 2018
The Cause of a Rare Neurological Disease is Identified
In a recent study, scientists sequenced the genome to find the mutation behind a disorder that causes blindness and paralysis....
JUN 23, 2018
Clinical & Molecular DX
JUN 23, 2018
Algorithm-Based Blood Test Diagnoses Autism
As a developmental disorder, autism spectrum disorders (ASD) can be diagnosed as early as 18 to 24 months of age, but often the diagnosis does not come unt...
JUN 30, 2018
Immunology
JUN 30, 2018
CD4 T Cells Responsible for Inflammatory Bowel Disease
A specific subset of immune cells could be targeted to better treat inflammatory bowel disease (IBD). A new University of Alabama at Birmingham study point...
JUL 13, 2018
Genetics & Genomics
JUL 13, 2018
Detecting Leukemia Before it Starts Growing
Researchers have found ways to identify people who may develop an aggressive type of blood cancer while they are still healthy....
Loading Comments...